Autopsy report · NCT01830101

A Phase III Study of Re-Irradiation in Recurrent Glioblastoma

“This study will not be proceeding due to lack of funding from anticipated sources”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

AHS Cancer Control Alberta

Sponsor type

University, hospital or other

Conditions

Recurrent Glioblastoma

Interventions

TMZ plus concurrent re-irradiation; Temozolomide

Participants

0

Sites

1

Countries

Canada

Trials that died the same way

• DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation
  “Further funding was not approved for this study” (83% match in meaning)
• Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
  “Lack of funding to support the study” (83% match in meaning)
• Prevalence of Hepatitis B Infection in the Galilee Region, Israel
  “The study was not carried out due to lack of funding and budget problems” (81% match in meaning)
• Regulation of the Release of Inflammatory Mediators From Blood Leukocytes
  “No funding for the study” (80% match in meaning)
• Study of EQU-001 for Uncontrolled Focal Onset Seizures
  “insufficient funding to complete the study” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.